Why the study?
Does rivaroxaban reduce venous thromboembolism in acutely ill medical patients compared to enoxaparin?
Does rivaroxaban reduce venous thromboembolism in acutely ill medical patients compared to enoxaparin?
Extended-duration rivaroxaban reduces VTE risk in acutely ill medical patients but is associated with an increased risk of bleeding.
Extended rivaroxaban may be considered for selected high-risk medical patients despite bleeding trade-off; extends RCT evidence on post-discharge thromboprophylaxis duration.
In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.).
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: